[Featured Stock] Lunit Collaborates with Global Big Pharma..."AI Biomarker Growth Potential Becomes Visible"

Lunit is on the rise. It is interpreted that the collaboration with global big pharma and securities firms' analysis predicting accelerated growth in the United States have influenced this trend.

As of 2:41 PM on the 20th, Lunit was trading at 61,800 KRW, up 800 KRW (1.31%) from the previous trading day.

Lee Sangheon, a researcher at iM Securities, said, "In November last year, Lunit signed a strategic collaboration agreement with AstraZeneca to develop an AI-based digital pathology solution targeting non-small cell lung cancer." He added, "AstraZeneca is a global big pharma company with sales exceeding 60 trillion KRW as of 2023."

He explained, "The core of the contract with AstraZeneca is to utilize Lunit's AI biomarker, Lunit SCOPE, to predict the possibility of EGFR mutations commonly occurring in non-small cell lung cancer." He continued, "Since the contract with AstraZeneca has opened the path to commercialization, it is expected to serve as a starting point for establishing an additional revenue base using Lunit SCOPE."

He added, "Lunit SCOPE analyzes the patterns of immune cells surrounding cancer cells using AI to predict responsiveness to immune checkpoint inhibitors, thereby increasing the possibility of treatment."

He emphasized, "The subsidiary, Volpara, currently supplies software solutions and platforms for early breast cancer diagnosis and management to more than 2,000 medical institutions, accounting for one-third of all mammography screening centers in the United States." He continued, "Most importantly, by leveraging Volpara's distribution network, discussions on product supply with U.S. medical institutions are expanding, and as product supply becomes visible in the U.S. in the future, growth is expected to accelerate."

This content was produced with the assistance of AI translation services.